Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease: CAMCO trial

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Polastro L, El Hachem G, Hendlisz A. Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer. Curr. Opin Oncology 30(4), 269–275 (2018).
  MedlineGoogle Scholar
• 2. Quénet F, Elias D, Roca L et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet. Oncol. 22(2), 256–266 (2021).
  Medline CASGoogle Scholar
• 3. Zhang GQ, Taylor JP, Stem M et al. Aggressive multimodal treatment and metastatic colorectal cancer survival. J. Am. College Surg. 230(4), 689–698 (2020).
  MedlineGoogle Scholar
• 4. Shen C, Hu H, Cai Y et al. mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. Ann. Translat. Med. 10(4), 171 (2022).
  Medline CASGoogle Scholar
• 5. Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur. J. Surg. Oncol. 41(9), 1197–1203 (2015).
  MedlineGoogle Scholar
• 6. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14(12), 1208–1215 (2013). •• Proposed to assess the use of perioperative chemotherapy (i.e., before and after surgery) in a randomised phase III trial, even in patients with resectable disease – the rationale being that this method would treat micrometastatic disease. In patients without (readily) resectable disease, further aims were to increase the proportion of patients who had a complete resection and to reduce the size of liver metastases, therefore helping to improve results of hepatectomies. The benefit in progression-free survival (PFS) was observed in the perioperative chemotherapy group. This benchmark of 3-year disease-free survival of 34.5% was shown in this trial, which was used as a historical control in sample calculation.
  Medline CASGoogle Scholar
• 7. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7 (2017).
  Google Scholar
• 8. Doehner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N. Engl. J. Med. 373(12), 1136–1152 (2015).
  Medline CASGoogle Scholar
• 9. Wang X, Wang SS, Huang H et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325(1), 50–58 (2021). •• Reveals that administering capecitabine for 1 year post-treatment significantly enhances disease-free survival and other secondary end points compared with observation alone, indicating a potential beneficial strategy for improving outcomes in this challenging subtype of cancer.
  Medline CASGoogle Scholar
• 10. Simkens LH, Van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385(9980), 1843–1852 (2015).
  Medline CASGoogle Scholar
• 11. Luo HY, Li YH, Wang W et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann. Oncol. 27(6), 1074–1081 (2016). • Showed that maintenance therapy with a single agent of capecitabine can be considered an appropriate option following the induction of XELOX or FOLFOX in metastatic colorectal cancer (mCRC) patients with acceptable toxicities.
  Medline CASGoogle Scholar
• 12. Goey KKH, Elias SG, Van Tinteren H et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann. Oncol. 28(9), 2128–2134 (2017).
  Medline CASGoogle Scholar
• 13. Sonbol MB, Mountjoy LJ, Firwana B et al. The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials. JAMA oncology 6(3), e194489 (2020).
  MedlineGoogle Scholar
• 14. Al-Hajeili M, Serzan M, Prins P, Marshall J. P-056: Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRC. Ann. Oncol. 27(Suppl. 2), ii17–ii17 (2016). • Examines the potential benefits of maintenance therapy in mCRC patients who achieved no evidence of disease following surgical resection of liver metastases. Among 61 eligible patients, those receiving maintenance therapy exhibited a non-significant trend towards extended PFS, suggesting the possibility that higher risk patients might have been selected for maintenance therapy, warranting further investigation in a larger patient cohort.
  Google Scholar
• 15. Auber ML, Wen S, Hobbs G, Higa GM. Capecitabine as maintenance therapy for high-risk, resected colorectal cancer. Gastrointest. Tumors 8(2), 81–86 (2021). • Aimed to evaluate the effectiveness of capecitabine maintenance therapy following treatment according to guidelines in staged 2C, 3A, 3B, 3C or 4A colon or rectal cancer. Analyses of a cohort of 35 patients receiving capecitabine maintenance showed promising outcomes, with a 5-year event-free survival rate of 74% and evidence that maintenance therapy mitigates disease progression and related mortality.
  Medline CASGoogle Scholar
• 16. Hari DM, Leung AM, Lee J-H et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J. Am. College Surg. 217(2), 181–190 (2013).
  MedlineGoogle Scholar
• 17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 18. Xu RH, Shen L, Li J et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chin. J. Cancer 35, 13 (2016).
  Medline CASGoogle Scholar
• 19. Brandi G, De Lorenzo S, Nannini M et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J. Gastroenterol. 22(2), 519–533 (2016).
  Medline CASGoogle Scholar
• 20. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14(12), 1208–1215 (2013).
  Medline CASGoogle Scholar
• 21. Colon Cancer (Version 2. 2021). www.nccn.org/professionals/physician_gls/pdf/colon.pdf
  Google Scholar
• 22. Moretto R, Rossini D, Zucchelli G et al. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. Eur. J. Cancer 139, 81–89 (2020). • Showed that the benefit from chemotherapy intensification is independent of the metastatic spread extent and tumor burden.
  Medline CASGoogle Scholar
• 23. Miger J, Holmqvist A, Sun XF, Albertsson M. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med. Oncol. 31(3), 870 (2014).
  MedlineGoogle Scholar